[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516532":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":176,"collaborators":178,"id":182,"slug":183,"hasResults":184,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":23,"eligibilityCriteria":187,"healthyVolunteers":184,"sex":188,"minAge":189,"maxAge":23,"enrollmentInfo":190,"targetDuration":23,"studyType":193,"phases":194,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy Dose Dose Finding - Part 1","EXPERIMENTAL","TORL-4-500 iv once every 3 weeks",[13],"Drug: TORL-4-500",{"label":15,"type":10,"description":11,"interventionNames":16},"Expansion as Monotherapy - Part 2",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","TORL-4-500","antibody drug conjugate",[15,9],null,[25],{"name":26,"affiliation":5,"role":27},"Caroline Labib, PharmD","STUDY_CHAIR",[29],{"name":26,"role":30,"phone":31,"phoneExt":23,"email":32},"CONTACT","310-348-9636","caroline.labib@torlbio.com",[34,53,66,79,92,106,119,133,146,162],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Mayo Clinic Phoenix","RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-112.07404,33.44838,{"lat":46,"lon":45},[49,51],{"name":50,"role":30,"phone":23,"phoneExt":23,"email":23},"Mohamad Sonbol, MD",{"name":50,"role":52,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"facility":54,"status":36,"city":55,"state":56,"zip":57,"country":40,"countryCode":41,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Providence Medical Foundation","Fullerton","California","92835",{"type":43,"coordinates":59},[60,61],-117.92534,33.87029,{"lat":61,"lon":60},[64],{"name":65,"role":30,"phone":23,"phoneExt":23,"email":23},"Yung Lyou, MD",{"facility":67,"status":36,"city":68,"state":56,"zip":69,"country":40,"countryCode":41,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"UCLA - JCCC Clinical Research Unit","Los Angeles","90095",{"type":43,"coordinates":71},[72,73],-118.24368,34.05223,{"lat":73,"lon":72},[76],{"name":77,"role":30,"phone":78,"phoneExt":23,"email":23},"Lee Rosen, MD","310-829-5471",{"facility":80,"status":36,"city":81,"state":56,"zip":82,"country":40,"countryCode":41,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Torrance Memorial Physician Network","Torrance","90505",{"type":43,"coordinates":84},[85,86],-118.34063,33.83585,{"lat":86,"lon":85},[89,91],{"name":90,"role":30,"phone":23,"phoneExt":23,"email":23},"Justin Tiulim, MD",{"name":90,"role":52,"phone":23,"phoneExt":23,"email":23},{"facility":93,"status":36,"city":94,"state":95,"zip":96,"country":40,"countryCode":41,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Mayo Clinic Jacksonville","Jacksonville","Florida","32224",{"type":43,"coordinates":98},[99,100],-81.65565,30.33218,{"lat":100,"lon":99},[103,105],{"name":104,"role":30,"phone":23,"phoneExt":23,"email":23},"Yanyan Lou, MD",{"name":104,"role":52,"phone":23,"phoneExt":23,"email":23},{"facility":107,"status":36,"city":108,"state":95,"zip":109,"country":40,"countryCode":41,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Florida Cancer Specialists Lake Nona Drug Development Unit","Orlando","32827",{"type":43,"coordinates":111},[112,113],-81.37924,28.53834,{"lat":113,"lon":112},[116,118],{"name":117,"role":30,"phone":23,"phoneExt":23,"email":23},"Cesar Perez, MD",{"name":117,"role":52,"phone":23,"phoneExt":23,"email":23},{"facility":120,"status":36,"city":121,"state":122,"zip":123,"country":40,"countryCode":41,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":43,"coordinates":125},[126,127],-92.4699,44.02163,{"lat":127,"lon":126},[130,132],{"name":131,"role":30,"phone":23,"phoneExt":23,"email":23},"Andrea Wahner-Hendrickson, MD",{"name":131,"role":52,"phone":23,"phoneExt":23,"email":23},{"facility":134,"status":36,"city":135,"state":136,"zip":137,"country":40,"countryCode":41,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Virginia Cancer Specialists","Lexington","Virginia","22031",{"type":43,"coordinates":139},[140,141],-79.44282,37.78402,{"lat":141,"lon":140},[144],{"name":145,"role":30,"phone":23,"phoneExt":23,"email":23},"Alexander Spira, MD",{"facility":147,"status":36,"city":148,"state":149,"zip":150,"country":151,"countryCode":152,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"University Health Network, Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":43,"coordinates":154},[155,156],-79.39864,43.70643,{"lat":156,"lon":155},[159,161],{"name":160,"role":30,"phone":23,"phoneExt":23,"email":23},"Erica Tsang",{"name":160,"role":52,"phone":23,"phoneExt":23,"email":23},{"facility":163,"status":36,"city":164,"state":165,"zip":166,"country":151,"countryCode":152,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"McGill University Health Centre","Montreal","Quebec","H4A 3J1",{"type":43,"coordinates":168},[169,170],-73.58781,45.50884,{"lat":170,"lon":169},[173,175],{"name":174,"role":30,"phone":23,"phoneExt":23,"email":23},"Ramy Saleh, MD",{"name":174,"role":52,"phone":23,"phoneExt":23,"email":23},{"type":177,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[179],{"name":180,"class":181},"Translational Research in Oncology","OTHER","100516532","phase-1-a-phase-1-first-in-human-study-of-torl-4-500-in-patients-with-advanced-cancer-100516532",false,"NCT06005740","A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer","Inclusion Criteria:\n\n* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Has not recovered \\[recovery is defined as NCI CTCAE, version 5.0, grade ≤1\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-4-500\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding","ALL","18 Years",{"count":191,"type":192},70,"ESTIMATED","INTERVENTIONAL",[195],"PHASE1","This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.\n\nFor Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).",[198,199],"Advanced Solid Tumor","Hepatocellular Carcinoma",[201],"ADC","2025-02-27",{"date":204,"type":205},"2025-03-04","ACTUAL",{"date":207,"type":205},"2023-12-04",{"date":209,"type":192},"2026-10-31",{"name":5,"class":6},10]